ICON Central Laboratories Launches New Cytometry Services Offering
ICON
announced the launch of a new Cytometry Services offering from its Central Laboratories business unit. ICON Cytometry Services now offers clients two types of services to better support the testing requirements and development phase of a client’s compound.
ICON Cytometry Services’ full service solution allows clients to collaborate with ICON at the early stages of development to create compound-specific assays. Clients work with ICON Central Laboratories’ R&D team to develop a unique Flow Cytometry methodology, customised SOPs and agree on other special requirements including reporting. These customised Flow Cytometry panels can then be used throughout the compound development lifecycle. ICON Cytometry Services’ other service offering enables clients to choose from a wide range of fully validated assays and is often suited to the large scale, high-volume requirements of later phase global trials.
Commenting on the announcement, Tom O’Leary, President, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”
ICON Central Laboratories offers global Flow Cytometry services from its laboratories in New York, Dublin, Bangalore and Singapore.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
